Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | RARG | P13631 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480507 | 0.76 | KDM4E (0.50) | CSNK2A1CHEK1 | |
| SCHEMBL25609256 | 0.74 | MKNK1 (0.81) | CSNK2A1MKNK1CSNK2A2 | |
| SCHEMBL25609536 | 0.74 | MKNK1 (0.49) | CSNK2A1MKNK1RARBRARGCSNK2A2 | |
| SCHEMBL21774262 | 0.74 | CSNK2A1 (0.43) | CSNK2A1RARBRARGHRH3PDE4D | |
| SCHEMBL12632280 | 0.73 | PRKAB2 (0.49) | — | |
| SCHEMBL8249743 | 0.73 | CHEK1 (0.53) | CSNK2A1MKNK1RARBRARGCSNK2A2 | |
| SCHEMBL24188232 | 0.70 | LIMK1 (0.41) | MKNK1 | |
| SCHEMBL21774151 | 0.69 | CSNK2A1 (0.41) | CSNK2A1RARBRARGRARAIKBKB | |
| SCHEMBL12632281 | 0.69 | KMO (0.59) | MLYCD | |
| SCHEMBL10039295 | 0.69 | CSNK2A1 (0.66) | CSNK2A1RARBRARGCSNK2A2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701960-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | CSNK2A1 123/4885MKNK1 1765/4885RARB 1001/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | CSNK2A1 178/4885MKNK1 1960/4885RARB 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.